BIOSYENT INC

BIOSYENT INC

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubri... cation during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; ; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository for the healing of the anus and rectum; and Cysview, an adjunct to white-light cystoscopy for the detection and management of non-muscle invasive papillary bladder cancer. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. is headquartered in Mississauga, Canada.

BioSyent Inc_logo

Industry:
Company

Founded:
4/28/1947

Address:
2476 Argentia Road, Mississauga, ON, Canada Zipcode L5N 6M1

Country:
Canada

Phone:
905 206 0013

Market Cap:
96.12M
Total Revenue:
22.33M
Total Assets:
33.57M
Total Cash:
20.29M

Chairman: Rene C Goehrum


Key Executives
Name Title Pay Year Born
Mr. René C. Goehrum Chairman, CEO & Pres 399,115$ N/A
Mr. Robert J. March VP of Fin. & CFO 220,408$ N/A
Mr. Joost van der Mark VP of Corp. Devel. 206,178$ N/A
Ms. Neelu Atwal Director of HR N/A N/A
Mr. Alfred D'Souza Advisor N/A N/A



Financial & Stock
Exchange TSXV. Currency in CAD. Market state CLOSED
According to BioSyent Inc's financial reports the company's revenue in 2020 were 22.33M an increase( +4.76%) over the years 2019 revenue that were of 21.42M. In 2020 the company's total earnings were 3.8M while total earnings in 2019 were 4.37M(-25%).
Company's stock symbol is RX.V. Lastest price : 7.55. Total volume :150.00 Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.biosyent.com

  • Host name: server87.it4business.ca
  • IP address: 67.231.26.111
  • Location: Toronto Canada
  • Latitude: 43.6215
  • Longitude: -79.392
  • Timezone: America/Toronto
  • Postal: M5J

Loading ...
Loading ...


More informations about "BioSyent Inc" on Search Engine

BioSyent Inc.

Biosyent.com BioSyent Inc. BioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada.

BioSyent Inc.

Biosyent.com BioSyent is continuously looking to source pharmaceutical products that have been …

BioSyent Inc.

Biosyent.com BioSyent is continuously looking to source pharmaceutical products that have been …

BioSyent Inc.

Biosyent.com BioSyent Inc. BioSyent is continuously is looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective.

BIOYF Stock Price | BioSyent Inc. Stock Quote (U.S.: OTC)

Marketwatch.com BioSyent Inc. BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly,...

BIOSYENT INC. (RX.V) Stock Price, News, Quote & History

Finance.yahoo.com About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring...

BioSyent Inc - Company Profile and News - Bloomberg Markets

Bloomberg.com BioSyent Inc BioSyent, Inc. operates as a specialty pharmaceutical company. The Company manages licenses rights to pharmaceuticals and regulatory process. BioSyent serves in Canada.

RX Stock Price | BioSyent Inc. Stock Quote (Canada: TSX)

Marketwatch.com BioSyent Inc. BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly,...

Biosyent Inc (RX-X) Quote - The Globe and Mail

Theglobeandmail.com Biosyent Inc is a specialty pharmaceutical company engaged in developing pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn,...

BioSyent Inc. Profile - SEDAR

Sedar.com BioSyent Inc. Mailing Address: 2476 Argentia Road Suite 402 Mississauga, Ontario L5N 6M1: Head Office Address: 2476 Argentia Road Suite 402 Toronto, Mississauga L5N 6M1: Contact Name: Robert March: Principal Regulator: Ontario: Business e-mail address: [email protected]: Short Form Prospectus Issuer: Yes: Telephone Number: 905 206-0013 ...

Biosyent Inc | V.RX Stock Message Board & Forum | Stockhouse

Stockhouse.com Apr 07, 2021 · "Biosyent Inc is a specialty pharmaceutical company engaged in developing pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. The company through its subsidiaries sources acquires or in-licenses pharmaceutical products and markets the products.

Combogesic® - First Acetaminophen + Ibuprofen Combination

Newswire.ca BioSyent Pharma Inc. in-licensed Combogesic® for Canada from AFT Pharmaceuticals Ltd. who sell the product, either directly or through partners, in 37 other countries under various brand names...

BioSyent Virtual Events – Just another Network site

Biosyent.virtualeventservices.ca BioSyent Virtual Events. No event found! No event found! Frequently Asked Questions: What is the registration process? Click on the Register button under any of our webinars to register. You will be asked to fill out your contact details to complete your registration.

RX.CA | BioSyent Inc. Company Profile & Executives - WSJ

Wsj.com BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. Its products include FeraMAX 150, …

RX:Venture Stock Quote - BioSyent Inc - Bloomberg Markets

Bloomberg.com About BioSyent Inc BioSyent, Inc. operates as a specialty pharmaceutical company. The Company manages licenses rights to pharmaceuticals and regulatory process. BioSyent serves in Canada.

BioSyent Inc. (RX) | Stock Price | TMX Money

Money.tmx.com Apr 05, 2021 · Get the latest stock price for BioSyent Inc. (RX), plus the latest news, recent trades, charting, insider activity, and analyst ratings.

Buy, Sell or Hold: BioSyent Inc (RX-X) — Stock Predictions

Stockchase.com BioSyent Inc is a Canadian stock, trading under the symbol RX-X on the TSX Venture Exchange (RX-CV). It is usually referred to as TSXV:RX or RX-X Is BioSyent Inc a buy or a sell? In the last year, there was no coverage of BioSyent Inc published on Stockchase. Is BioSyent Inc a …

RX | BioSyent Inc. Profile | MarketWatch

Marketwatch.com BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. Its products include FeraMAX 150, …

BioSyent Inc. (CVE:RX) Just Reported And Analysts Have

Finance.yahoo.com BioSyent Inc. shareholders are probably feeling a little disappointed, since its shares fell 4.5% to CA$3.58 in the week after its latest full-year results.It was a credible result overall, with ...

BioSyent Inc | LinkedIn

Ca.linkedin.com Listed on the TSX Venture Exchange (TSXV: RX) BioSyent is a profitable growth oriented speciality pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical...

BioSyent Inc. (BIOYF) CEO René Goehrum on Q3 2020 Results

Seekingalpha.com Nov 26, 2020 · BioSyent Inc. (OTCPK:BIOYF) Q3 2020 Earnings Conference Call November 26, 2020 7:00 AM ET Company Participants . René Goehrum - President & CEO. René Goehrum. Hello, and welcome to the BioSyent ...

BIOSYENT INC Share Price - RX Share Price

Stockopedia.com The Biosyent Inc PE ratio based on its reported earnings over the past 12 months is 20.49.The shares are currently trading at C$7.3.. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors.

BioSyent Inc. Stock Price (RX) | Barron's

Barrons.com Mar 17, 2021 · View today's stock price, news and analysis for BioSyent Inc. (RX). Barron's also provides information on historical stock ratings, target prices, …

RX.CA | BioSyent Inc. Stock Price & News - WSJ

Wsj.com BioSyent Inc. options quotes data for sells and puts, including RX.CA last price, change and volume.

BioSyent Inc. Just Missed Earnings - But Analysts Have

Finance.yahoo.com BioSyent Inc. came out with its quarterly results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report.Revenues ...

BioSyent Inc. (BIOYF) Stock Price Today, Quote & News

Seekingalpha.com BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.

BIOSYENT INC. (RX.V) Latest Stock News & Headlines - Yahoo

Ca.finance.yahoo.com BioSyent Inc.'s (CVE:RX) Stock Has Fared Decently: Is the Market Following Strong Financials? Most readers would already know that BioSyent's (CVE:RX) stock increased by …

BioSyent Inc. (TSX Venture: RX.V) :: LD Micro

Ldmicro.com About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track ...

BIOSYENT INC. (RX.V) Stock Price, News, Quote & History

Ca.finance.yahoo.com About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track ...

BIOYF.PK - Biosyent Inc. Profile | Reuters

Reuters.com Biosyent Inc Q2 Earnings Per Share C$0.06 Biosyent Reports Q1 Earnings Per Share Of C$0.11 BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent …

BioSyent Signs Exclusive Agreement for Pain Management

Globenewswire.com Nov 25, 2019 · Under the Agreement, BioSyent Pharma Inc. also has rights to additional forms of Combogesic® - some of which have been approved in other countries and for which it intends to seek approval in Canada.

BIOSYENT INC. (RX.V) Company Profile & Facts - Yahoo Finance

Finance.yahoo.com BioSyent Inc., a specialty pharmaceutical company, through its subsidiaries, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and ...

Business Development Analyst Job in Mississauga, ON at

Ziprecruiter.com BioSyent is focused on commercializing products that provide a distinguishable benefit to patients and their healthcare providers and is known for its ability to effectively introduce new products.

BioSyent Inc. (OTCMKTS:BIOYF) Sees Significant Decline in

Mayfieldrecorder.com Apr 01, 2021 · BioSyent Inc. (OTCMKTS:BIOYF) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 4,600 shares, a decline of 28.1% from the February 28th total of 6,400 shares. Based on an average daily volume of 2,500 shares, the days-to-cover ratio is presently 1.8 days. BIOYF traded up $0.04 […]

RX | BioSyent Inc. Stock Price & News - WSJ

Wsj.com View the latest BioSyent Inc. (RX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

BIOYF: Dividend Date & History for Biosyent Inc - Dividend.com

Dividend.com Biosyent Inc Dividend policy None Price as of: MAR 18, 10:39 AM EDT $5.84 +0.08 +1.39% Watchlist Overview. Compare. Payout Estimate. New. Payout History. Trading Ideas. News & Research. Company Profile. Home Dividend Stocks Health Care Biotech Pharma Specialty Pharma Biosyent Inc (BIOYF) Overview. Home

BIOSYENT INC. : Shareholders Board Members Managers and

Marketscreener.com BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused ...

BioSyent Releases Financial Results for Fourth Quarter and

Financialpost.com Mar 17, 2021 · About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track ...

BioSyent Inc. hiring Business Development Analyst in

Ca.linkedin.com BioSyent is focused on commercializing products that provide a distinguishable benefit to patients and their healthcare providers and is known for its ability to effectively introduce new products. BioSyent is actively sought out as the Canadian market partner of choice by brand innovators with niche or specialty products looking for a trusted ...

BIOSYENT INC. : Shareholders Board Members Managers and

Marketscreener.com BIOSYENT INC. : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Toronto Stock Exchange: RX ...

RX.CA | BioSyent Inc. Analyst Estimates & Rating – WSJ

Wsj.com BioSyent Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RX.CA updated stock price target summary.

BioSyent Announces Grant of Restricted Share Units | IT

Itbusinessnet.com Mar 20, 2021 · About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or ...

Biosyent Inc | V.RX Stock Message Board & Forum | Stockhouse

Stockhouse.com Dec 16, 2020 · "Biosyent Inc is a specialty pharmaceutical company engaged in developing pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. The company through its subsidiaries sources acquires or in-licenses pharmaceutical products and markets the products.

BioSyent Inc. (TSX Venture: RX.V) :: LD Micro

Ldmicro.com BIOSYENT SCHEDULES Q4 AND FULL YEAR 2019 EARNINGS RELEASE FOR MARCH 18, 2020. Stock Information for BioSyent Inc. Loading . Please wait while we load your information from QuoteMedia. More Recent News About BioSyent Inc. BioSyent …

Biosyent Inc (RX) Quote - XTSX | Morningstar

Morningstar.com Biosyent Inc is a specialty pharmaceutical company engaged in developing pharmaceutical and healthcare products. Its products include FeraMAX 150, …

Biosyent Announces Launch of New FeraMAX® Pd Therapeutic

Globenewswire.com Nov 05, 2020 · MISSISSAUGA, Ontario, Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX ® Pd Therapeutic 150, the ...